Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.32 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700232 | 0.82 | METAP2 (0.35) | AAK1 | |
| SCHEMBL6294857 | 0.74 | CTSL (0.47) | — | |
| SCHEMBL6300344 | 0.74 | EPHX1 (0.33) | — | |
| SCHEMBL6749612 | 0.73 | LARS1 (0.34) | AAK1LARS1SLC7A5 | |
| SCHEMBL11917585 | 0.65 | SLC7A5 (0.45) | AAK1LARS1SLC7A5ARG1ARG2 | |
| SCHEMBL7523273 | 0.62 | CTSK (0.47) | — | |
| SCHEMBL7375829 | 0.61 | EPHX1 (0.49) | DPP4DPP8DPP9DPP7SLC7A5 | |
| SCHEMBL7375831 | 0.61 | EPHX1 (0.49) | DPP4DPP8DPP9DPP7SLC7A5 | |
| SCHEMBL13995144 | 0.61 | EPHX1 (0.53) | DPP4DPP8DPP9DPP7SLC7A5 | |
| SCHEMBL7442268 | 0.61 | CTSK (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | AAK1 1660/4885LARS1 2218/4885DPP4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.